Introduction
The cyclin-dependentk inase (CDK)f amily consistso fm embers thata re key regulators of the cell-divisionc ycle (cell-cycleC DKs), involved in regulation of gene transcription (transcriptionalC DKs), ando fm embers with other functions( e.g.,C DK5). Whereasc ellcycleC DKs1 ,2 ,3 ,4a nd 6a re required fort he correctt iming and order of events of the cell-division cycle, transcriptionalC DK7 and CDK9 regulate the activity of RNA polymerase II viap hosphorylation of the carboxy-terminal domain( CTD). Since their discovery,C DKs haveb een considereds trong prospective targets for an ew generation of anticancer drugs. [1] Although numerous pharmaceutical companieshave initiatedd rug discoverd 1c,2]
Positive transcriptione longation factor b( PTEFb)i saheterodimer of CDK9 and one of four cyclin partners, cyclin T1, cyclin K, cyclin T2a or cyclin T2b. Whereas CDK9 is exclusively involved in transcriptional regulation, CDK7 in addition participates in cell-cycle regulation as aC DK-activating kinase. Transcription of genes by RNA polymerase II is initiated by assembly of the preinitiation complex at the promoter region and phosphorylation of Ser5and Ser7 of the CTD by CDK7/cyclinH. For most genes, RNA polymerase II stops mRNA transcription after it has moved2 0-40nucleotides along the DNA template. This promoter-proximal pausingo fR NA polymerase II is mediated by negative elongation factorsa nd is recognized as a major controlm echanismt or egulate expression of rapidlyi nduced genes in response to av ariety of stimuli. [3] PTEFb is crucially involved in overcoming promoter-proximal pausing of RNA polymerase II and transition into ap roductive elongation state by phosphorylation of Ser2 of the CTD, as well as by phosphorylation and inactivation of negative elongation factors. Deregulated kinase activity of CDK9 of the PTEFb heterodimer is associated with av ariety of human pathological conditions such as hyperproliferative diseases (e.g.,c ancer), virally induced infectious diseases and cardiovascular diseases. [4] PTEFb-mediated transcription of short-lived, antiapoptotic survival proteins,s uch as Mcl-1, and oncogenes, such as c-MYC, plays ac riticalr ole in cancer cell growth and survival. In addition, these proteins exhibit important functions in the development of resistance to chemotherapy.I nhibition of PTEFb/CDK9 resultsi nt he rapid depletion of short-lived mRNA transcripts of these important survival proteins ando ncogenes. Thus, selective, transient inhibition of exclusively transcription-regulatSelectivei nhibition of exclusively transcription-regulating PTEFb/CDK9 is ap romising new approachi nc ancer therapy. Startingf rom lead compound BAY-958, lead optimization efforts strictly focusing on kinase selectivity,p hysicochemical and DMPK properties finally led to the identification of the orally available clinicalc andidate atuveciclib (BAY1 143572).
Structurally characterized by an unusual benzyls ulfoximine group, BAY1 143572 exhibited the besto verall profile in vitro and in vivo, includingh igh efficacy and good tolerability in xenograft modelsi nm ice andr ats. BAY1 143572 is the first potent and highly selective PTEFb/CDK9 inhibitor to enter clinical trials forthe treatment of cancer.
[a] Dr.U.L ücking, Dr.A .S cholz,D r. P. Lienau,D r. G. Siemeister ing PTEFb/CDK9 is ap romising new approach in cancert herapy. [5] We now report the identification of atuveciclib (BAY1 143572, Figure 1 ), the first potent andh ighly selective PTEFb/CDK9 inhibitor that enteredc linical trials. Startingf rom lead compound BAY-958, which displayed potent PTEFb-inhibitory activity and high kinase selectivity in vitro, lead optimization by ac ollaborative effort involving medicinal chemistry, pharmacology,D MPK, structuralb iology and computational chemistry led to the identification of the orallyavailableclinical candidate BAY1 143572. Structurally characterizedbya nu nusual benzyl sulfoximine group, BAY1 143572e xhibited the most promisingo verall profilew ith respect to potency, kinase selectivity,p hysicochemical and DMPK properties, and antitumour efficacy in animal models.
Results and Discussion
Search for low-molecular-weight PTEFb/CDK9 inhibitors Attracted by the encouraging biological rationale, we set course to identify ap otent, highly selective and orally applicable PTEFb/CDK9 inhibitore xclusively targeting oncogenic transcriptionf or the treatment of cancer. Special attention was paid to the aspecto fh igh selectivity with respectt ok inases in general as well as within the CDK family,i np articular high CDK9 selectivity.S uch CDK9 selectivity was anticipated as being crucial for the differentiation of ap otentialc andidate from cell-cycle-addressing selectiveC DK inhibitors (like the CDK4/6i nhibitor palbociclib [6] )a nd from pan-CDK inhibitors (like dinaciclib [7] or roniciclib [8] ), because adifferentiated activity and tolerability profile can be expected. Furthermore, favorable physicochemical and DMPK properties, which have been key hurdles in many kinasei nhibitor projects, [9] were of high importance.
In the search for as uitable lead structure, triazine BAY-958 (LDC 526, Figure 1 ) attracted our attention, as this compound provedt ob eap otent PTEFb/CDK9 inhibitor that also displayed very high kinase selectivity,e ven within the CDK family (in-house kinase panel:I C 50 CDK9/CycT1:1 1nm,s electivity vs. CDK2:9 8, see Ta ble 3; Millipore panel:I C 50 CDK9/CycT1:5n m, selectivity vs. other CDKs: > 90, see Table 4 ). BAY-958a lso exhibited good antiproliferativea ctivity in vitro, for example against HeLa cells (IC 50 :1 000 nm)a nd MOLM-13 cells (IC 50 : 280 nm). In vitro pharmacokinetic studies with BAY-958 demonstrated high metabolic stabilityi nr at hepatocytes (ratHep) and liver microsomes( ratLM), resulting in al ow predicted blood clearance (CL b )o f0 .33 Lh À1 kg À1 and 0.48 Lh À1 kg
À1
,r espectively (see Ta ble3).
On the other hand, BAY-958h as ar ather low aqueous solubility of 11 mg L À1 at pH 6.5. Moreover,w erecorded av ery moderate permeability coefficient (P app A!B) of 22 nm s À1 and ah ighe fflux ratio of 15 in Caco-2c ells, as well as ab lood/ plasma partitioning in rats of about 3:1( see Table 3 ). Pharmacokinetic studies in rats in vivo revealed al ow blood clearance (CL b :0 .5 Lh À1 kg
), ah igh volumeo fd istribution (V ss : 1.4 Lkg
)a nd as hort half-life (t 1/2 :0 .7 h) of BAY-958. After oral administration, al ow bioavailability of only 10 %w as observed.
Due to the slow absorption and low bioavailability of BAY-958 observed in the rat pharmacokinetic studies, the hydrochlorideo fB AY-958 wasu sed in as ubsequent mousex enograft study to analyze the in vivo efficacy.D aily oral administration of BAY-958 hydrochloride at 30 or 40 mg kg À1 resulted in a marked inhibition of tumor growth with treatment-to-control (T/C) ratios of 0.16 and 0.12, respectively,a tt he end of the experiment (Figure2). Additionally,t here was excellent tolerability upon treatment with BAY-958 hydrochloride, with ab ody weightc hange of less than 10 %a nd no fatal toxicities. Nevertheless, due to the unfavorable physicochemical and DMPK properties of BAY-958, we elected to search for ac ompound with an improved overall profile. . Antitumore fficacy of BAY-958h ydrochloride in an MOLM-13 human AML model in mice. Treatments were started three days after tumor cell inoculation. A) Tumor growth. Asterisks indicate statistical significance relative to the vehicle control, calculated using the mean tumor areas at the time point when the vehicle group was sacrificed (*p < 0.047, ***p < 0.001). B) Body weight change expressed as ap ercentage of the starting weight.
Structural variation of lead compound BAY-958
Lead compound BAY-958 and structurally relatedd erivatives were easily accessible by straightforwardc hemistry (Scheme 1).
In the first step, commercial 2,4-dichloro-1,3,5-triazine (1)w as reactedw ith as uitable anilineu nder basic conditions to give the corresponding N-aryl-4-chloro-1,3,5-triazin-2-amine 2.I n the second step, the crude coupling product 2 was reacted with aboronic acid derivativetog ive the desired product 3.
The binding mode of lead compound BAY-958 with CDK9 was investigated by docking experiments ( Figure 3 ). According to these modeling studies, bindingt ot he hinge region of CDK9 is mediated by the triazine core and the aniline NH. The benzyls ulfonamide moiety is directed towardt he exit of the ATPb inding pocket,w hereas the methoxyphenyl substituent points toward the ribose pocket. Favorable interactions include two hydrogen bonds to the hinge regiona nd two hydrogen bonds formed by the amino part of the sulfonamideg roup, as well as a p-stacking interaction of the methoxyphenyl moiety with the Phe103 gatekeeper residue. In addition, aw eak hydrogen bond betweent he para-fluoro substituent and the catalytic Lys48 may be postulated. [10] However, the high CDK9 selectivity of BAY-958, versus other CDKs, could not be rationalized.
Analyzing the chemical structure of lead compound BAY-958, the chemistry team was well-disposed toward inclusion of the central triazine core. The benzyls ulfonamide group, however,raised concerns:due to its polarity,high number of heteroatomsa nd multiple hydrogen-bonding properties, it was suspected of contributing significantly to the low aqueous solubility of BAY-958, the rather moderate Caco-2 permeability and the high efflux ratio. Furthermore, the acidity properties and potentialinstability of the benzyl sulfonamide group were considered and ultimately triggered the evaluationo fp otential structuralalternatives at this position (Table 1) .
Sulfones aroused our attention, because analogue 4 exhibited as imilar CDK9-inhibitory activity as BAY-958 in our biochemicala ssay in vitro [IC 50 CDK9/CycT1 (in-house), 4:2 4nm vs. BAY-958:1 1nm,s ee Ta ble 1],e ven though the sulfone group cannot form similar hydrogen bondsa st he amino part of the sulfonamide group (Figure 3 ). Sulfone 4 also exhibited similar selectivity against cell-cycle kinaseC DK2 (ratio of IC 50 valuesC DK2/CDK9, 4:6 7v s. BAY-958:9 8) and antiproliferative activity against HeLa cells (IC 50 4:1 .5 mm vs. BAY-958:1 .0 mm). To address the initial concerns regarding the stability and acidity of ap olar functional group at the benzylic position, analogues 5 and 6 were synthesized;h owever,i nt his sulfone series,t he removal of the methylene group from 4 (compound 5)o rt he introduction of an additional methylene group to 4 (compound 6)r esulted in both decreased PTEFb/CDK9a ctivity and significantly reduced selectivity against cell-cyclek inase CDK2 (Table 1) . This finding was quite surprising, as the sulfone group is directed towardt he exit of the ATPb inding pocket. Furthermore, the introductiono fm ethyl or even fluoro substituent(s) at the benzylic position was not well-tolerated with regard to activity against CDK9 (compounds 10, 11, 13), as well as selectivity against CDK2 (compounds 10-13). Inclusion of an annulated ring system (compounds 7, 8)a lso resultedi n poor CDK9 selectivity.
Extensive structural variation on the eastern side of lead compound BAY-958 also revealed ar ather steep SAR with respect to selectivity against CDK2 and potency( Ta ble 2).
The para-fluoro substituent on the phenyl ring of BAY-958 provedt ob eb eneficial for antiproliferative activity in vitro:a nalogues 14 (p-H) and 15 (p-Cl) both displayed decreasedI C 50 valuesa gainst HeLa cells (IC 50 14:1 .6 mm, 15:3 .8 mm vs. BAY-958:1 .0 mm). Pyridyla nalogue 16 exhibited significantly reduced activity against CDK9 in the biochemical assay (IC 50 16: 1800 nm). Moreover,a northo-alkoxys ubstituent was crucial for the desired CDK9 selectivity,asw ell as in vitro potency;various functional groupsw ere evaluated as potentials tructural alternatives, but all such analogues displayed significantly reduced selectivity against CDK2 and inhibitory activity against CDK9 (see Ta ble 2f or selected examples;e .g., [17] [18] [19] [20] [21] [22] . Introduction of as terically larger alkoxy substituent, especiallyabenzyloxy group, resulted in significantly improved potency;h owever, most of these compounds suffered from very low metabolic stabilityi nvitro. For instance, whilst benzyla nalogue 23 provedt ob eahighly potent CDK9 inhibitor,i te xhibited low metabolic stabilityi nl iver microsome preparations of human, mouse and rat origin, with recovery of the parent compound Figure 3 . Dockingmode of BAY-958 in complex with CDK9. The compound was docked into apublished X-raycomplex of CDK9/CycT1( PDB ID:3MY1) using the Glide docking program.The sulfonamide moiety forms two hydrogen bonds, one to Glu107 (main chain) and the other to Asp109 (side chain). For the substituted phenyl ring attached to the triazine, a p-stacking interaction with Phe103 and aweak hydrogen bond to Lys48 maybep ostulated.
Scheme1
.Generalsynthesis of triazine-based PTEFbi nhibitors. Reagents and conditions:a)R after incubation for 60 minutes of 0%,0 .2 %a nd 0%,r espectively.
Identification of BAY1 143572
Since the late discovery of the sulfoximine group in 1949, [11] sulfoximine chemistry [12] has been rather an iche discipline. Applications have mainly centered around the use of sulfoximines as either chiral auxiliaries [13] or ligandsi na symmetric catalysis. [14] Until very recently,t he sulfoximine group has rarely been used in life science approaches, even though it offersaunique combination of interesting properties, namely high stability, favorable physicochemical properties, hydrogen-bond acceptor/ donor functionalities and structural diversity. [15] Lately,however, there has been ar apidly increasing interest in sulfoximines as pharmacophores in the life sciences. [15, 16] Our prior,l ong-standing interesti ns ulfoximinesi nm edicinal chemistry hadb een exclusively focused on aryl sulfoximines; [17] nevertheless,w e then decided to evaluate ab enzyl sulfoximine analogueo f BAY-958.
In the corresponding synthesis (Scheme 2), thioether 25, prepared from the commercial benzylc hloride 24,w as oxidized and the resulting sulfoxide 26 was converted into sulfoximine 27 using the rhodium-catalyzed method of Okamura and Bolm. [18] Next, ap rotectingg roup was introduced at the sulfoximine nitrogen to provide 28.T he nitro group of 28 was reduced and the resulting aniline 29 reactedw ith 2,4-dichloro-1,3,5-triazine (1)u nder basic conditions. The crude coupling product 30 was used in as ubsequent Suzuki reaction to yield compound 31.F inally,d eprotection and chiral HPLC separation provided the (R)-sulfoximine BAY1 143572 and its enantiomer 32. [19] The stereochemistry at the sulfur of the sulfoximine group was determined by X-ray crystallography of the corresponding N-acetyl derivative 33 (Figure 4 ).
In comparison with BAY-958 and benzyls ulfone 4,b enzyl sulfoximine BAY1 143572c learly exhibited the best overall profile in vitro and in vivo (Table 3 ). BAY1 143572i sapotent and highly selective CDK9 inhibitor (IC 50 CDK9/CycT1:1 3nm,r atio of IC 50 values CDK2/CDK9:1 00). The selectivity of BAY1 143572 within the CDK family is even higher than that of lead com- For the subsequent in vivo studies, two xenograft models of human acute myeloid leukemia (AML) were selected, as it is well known from the preclinical literature [21] that this indication is dependento no ncogenic transcription and also the only indicationwhere nonselective CDK inhibitors with CDK9 inhibitory activity have reached randomized phase 2c linical trials (NCT01349972, NCT00634244,N CT00795002). Of note, BAY1 143572d id not show relevant activity against Flt3 in the Merck Millipore KinaseProfiler TM panel (see the Supporting Information); therefore, the possibility that in vivo activity of the compound might be partially mediated by Flt3 inhibition in Flt3-alterated MOLM-13 and MV4-11c ells can be excluded.
In in vivo efficacy studies in the MOLM-13 xenograft model in mice, BAY1 143572 demonstrated greaterp otency and highera ntitumor efficacy than benzyl sulfone 4 ( Figure 5A and Ta ble 5). Daily treatmentw ith benzyl sulfone 4 at the maximum tolerated dose of 20 mg kg À1 revealed no efficacy (T/C ratio of 0.73, p = 0.073). In contrast, daily administrationo f BAY1 143572a t6 .25 or 12.5 mg kg À1 resulted in ad ose-dependent antitumore fficacy with aT /C ratio of 0.64 and 0.49, respectively (p < 0.001). In as eparate experiment with ah igher daily dose of 20 or 25 mg kg À1 BAY1 143572, antitumore fficacy with aT /C ratio of 0.41 and 0.31, respectively,w as observed (p < 0.001). The 25 mg kg À1 once daily dose is the maximum tolerated dose in nude mice. Furthermore, BAY1 143572admin-istereda t2 5o r3 5mgkg
À1
,t hree days on /t wo days off, resulted in aT /C ratio of 0.33 and0 .20, respectively (p < 0.001), suggesting ap ossible flexibility for the selection of ac linical dosing regimen ( Figure 5B and Ta ble 5). Treatmentw ith BAY1 143572w as well-tolerated, as demonstrated by less than 10 %m ean body weight reduction throughout the study.
To further substantiatet he antitumor efficacy,B AY 1143572 was evaluated in an MV4-11h umana cutem yeloid leukemia modeli nn ude rats. Of note, the antiproliferativea ctivityo f BAY1 143572a gainst MV4-11c ells (IC 50 :8 90 nm) andH eLa cells (IC 50 :920 nm) in vitro is similar,and is slightly improved against MOLM-13 cells (IC 50 :3 10 nm).D aily oral administration of BAY1 143572a t1 2mgkg À1 for 14 days (maximum tolerated dose) resulted in almost complete tumor remission, followed by delayed regrowtha fter cessation of the treatment (Figure 5C ). At the conclusiono ft he experiment (57 days after initial inoculation), there was no tumor regrowth in nine of the 12 test animals. Due to the promising overall profile in vitro and in vivo, benzyls ulfoximine BAY1 143572 was selected as the development candidate and entered phase 1c linical trials in patients with advanced cancera nd leukemia (NCT01938638, NCT02345382).
[22]
Conclusions
The benzyls ulfoximine atuveciclib (BAY1 143572) is ap otent and highly selective, oral PTEFb/CDK9 inhibitor.D uring lead optimization, as urprisingly steep SAR with regard to the key optimization parameters kinase selectivity and potency was recorded. BAY1 143572c learly exhibited the most promising [a] Treatment-to-control( T/C) ratios and statistical significances were calculated using the meant umor areasa tt he time pointwhenthe vehicle group was sacrificed. Asterisks indicates tatistical significance (p < 0.001) relative to the vehicle control.
[b] The maximum bodyw eight change (BWC) expresseda sa percentage of the starting weight, for duration of the treatment. 
Experimental Section
Kinasea ssays CDK9/CycT1:R ecombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTAa ffinity chromatography,w ere purchased from Invitrogen (Cat. no. PV4131). As substrate for the kinase reaction, the biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amide form) was used, which is commercially available (e.g.,f rom JERINI Peptide Te chnologies, Berlin, Germany). For assays, 50 nL of a1 00-fold concentrated solution of the test compound in DMSO was pipetted into ab lack, low-volume, 384-well microtiter plate (Greiner BioOne, Frickenhausen, Germany);2mLo fasolution of CDK9/CycT1 in aqueous assay buffer [50 mm Tris·HCl pH 8.0, 10 mm MgCl 2 ,1 .0 mm dithiothreitol, 0.1 mm sodium orthovanadate, 0.01 %( v/v)N onidet P-40 (Sigma)] was added, and the mixture was incubated for 15 min at 22 8Ct oa llow pre-binding of the test compound to the enzyme before the start of the kinase reaction. Then, the kinase reaction was started by the addition of 3 mLo fasolution of adenosine triphosphate (ATP,1 6.7 mm; final concn in the 5 mLa ssay volume:1 0mm)a nd substrate (1.67 mm; final concn in the 5 mL assay volume:1mm)i na ssay buffer,a nd the resulting mixture was incubated for 25 min at 22 8C. The concentration of CDK9/CycT1 was adjusted depending on the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range:t ypical concentrations were in the order of 1 mgmL À1 .T he reaction was stopped by the addition of 5 mLo fasolution of TR-FRET detection reagents [0.2 mm streptavidin-XL665 (Cisbio Bioassays, Codolet, France), 1nm anti-RB(pSer807/pSer811) antibody (BD Pharmingen, Cat. no. 558389) and 1.2 nm LANCE EU-W1024 labeled anti-mouse IgG antibody (PerkinElmer,p roduct no. AD0077)] in an aqueous EDTAs olution [100 mm EDTA, 0.2 %( w/v)b ovine serum albumin (BSA) in 100 mm HEPES/NaOH pH 7.0].T he resulting mixture was incubated for 1hat 22 8Ct oa llow the formation of ac omplex between the phosphorylated biotinylated peptide and the detection reagents. Subsequently,t he amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the europium chelate to the streptavidin-XL. Therefore, the fluorescence emissions at 620 nm and 665 nm, after excitation at 350 nm, were measured with aT R-FRET reader [e.g.,P HERAstar (BMG Labtechnologies, Offenburg, Germany) or ViewLux (PerkinElmer)].T he ratio of the emissions at 665 nm and 620 nm was taken as the measure of the amount of phosphorylated substrate. The data were normalized (enzyme reaction without inhibitor = 0% inhibition, all other assay components but no enzyme = 100 %i nhibition). Usually the test compound was tested on the same mi- Figure 5 . Antitumor efficacy in two AML models in mice and rats. A, B: Antitumorefficacy of BAY1 143572i nanM OLM-13 human AML model in mice. A) Tumor growth in mice treatedw ith compound 4 or BAY1 143572. Treatments werestarted three days after tumor cell inoculation. B) Tumor growth in mice treatedw ith BAY1 143572once daily (QD) or with an intermittent 3dayson/2 daysoff dosing schedule. Treatments weres tarted 4daysafter tumorcell inoculation.C)Antitumore fficacy of BAY1 143572ina nM V4-11 human AMLm odel in rats. Tumor growthi nrats treated with vehicle or BAY1 143572.T reatments were started 13 days after tumor cellinoculation and were continued for 14 days, until the vehiclegroup was sacrificed. Asterisks indicate statistical significance relative to the vehicle control, calculated using the mean tumorareas at the time pointwhen the vehiclegroup was sacrificed (***p < 0.001, ns = not significant).
ChemMedChem 2017, 12,1776 -1793 www.chemmedchem.org 2017 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim crotiter plate at 11 different concentrations in the range of 20 mm to 0.1 nm (20 mm,5 .9 mm,1 .7 mm,0 .51 mm,0 .15 mm,4 4nm,1 3nm, 3.8 nm,1 .1 nm,0 .33 nm and 0.1 nm;t he dilution series was prepared separately before the assay on the 100-fold concentrated solution in DMSO by serial 1:3.4 dilutions) in duplicate for each concentration. IC 50 values were calculated using afour-parameter fit.
CDK2/CycE:R ecombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathione-Sepharose affinity chromatography,w ere purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction, the biotinylated peptide biotin-Ttds-YISPLK-SPYKISEG (C-terminus in amide form) was used, which is commercially available (e.g.,f rom JERINI Peptide Technologies, Berlin, Germany). For assays, 50 nL of a1 00-fold concentrated solution of the test compound in DMSO was pipetted into ab lack, low volume, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany);2 mLo fasolution of CDK2/CycE in aqueous assay buffer [50 mm Tris·HCl pH 8.0, 10 mm MgCl 2 ,1 .0 mm dithiothreitol, 0.1 mm sodium orthovanadate, 0.01 %( v/v)N onidet P-40 (Sigma)] was added, and the mixture was incubated for 15 min at 22 8Ct o allow pre-binding of the test compound to the enzyme before the start of the kinase reaction. Then, the kinase reaction was started by the addition of 3 mLo fasolution of ATP( 16.7 mm; final concn in the 5 mLa ssay volume:1 0 mm)a nd substrate (1.25 mm; final concn in the 5 mLa ssay volume:0 .75 mm)i na ssay buffer,a nd the resulting mixture was incubated for 25 min at 22 8C. The concentration of CDK2/CycE was adjusted depending on the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range;t ypical concentrations were in the order of 130 ng mL À1 .T he reaction was stopped by the addition of 5 mLo fa solution of TR-FRET detection reagents [0.2 mm streptavidin-XL665 (Cisbio Bioassays, Codolet, France), 1nm anti-RB(pSer807/pSer811) antibody (BD Pharmingen, Cat. no. 558389) and 1.2 nm LANCE EU-W1024 labeled anti-mouse IgG antibody (PerkinElmer,p roduct no. AD0077)] in an aqueous EDTAs olution [100 mm EDTA, 0.2 %( w/v) BSA in 100 mm HEPES/NaOH pH 7.0].T he resulting mixture was incubated for 1h at 22 8Ct oa llow the formation of ac omplex between the phosphorylated biotinylated peptide and the detection reagents. Subsequently,t he amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the europium chelate to the streptavidin-XL. Therefore, the fluorescence emissions at 620 nm and 665 nm, after excitation at 350 nm, were measured with aT R-FRET reader [e.g.,P HERAstar (BMG Labtechnologies, Offenburg, Germany) or ViewLux (PerkinElmer)].T he ratio of the emissions at 665 nm and 620 nm was taken as the measure of the amount of phosphorylated substrate. The data were normalized (enzyme reaction without inhibitor = 0% inhibition, all other assay components but no enzyme = 100 %i nhibition). Usually the test compound was tested on the same microtiter plate at 11 different concentrations in the range of 20 mm to 0.1 nm (20 mm,5 .9 mm,1 .7 mm,0 .51 mm,0 .15 mm,4 4nm,1 3nm, 3.8 nm,1 .1 nm,0 .33 nm and 0.1 nm;t he dilution series was prepared separately before the assay on the 100-fold concentrated solution in DMSO by serial 1:3.4 dilutions) in duplicate for each concentration. IC 50 values were calculated using afour-parameter fit.
Merck Millipore CDK assays:A ssays were performed according to the Merck Millipore KinaseProfiler TM standard protocols, with an ATPc oncentration of 10 mm.
Proliferation assay
HeLa human cervical tumor cells (CCL-2) were obtained from the American Type Culture Collection (Manassas, USA) and MOLM-13 human acute myeloid leukemia cells (ACC 554) were obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). Authentication of cell lines was conducted at the German Collection of Microorganisms and Cell Cultures via PCR-based DNA profiling of polymorphic short tandem repeats. Cells were propagated under the suggested growth conditions in ah umidified 37 8Ci ncubator.P roliferation assays were conducted in 96-well plates at densities of 3000 (HeLa) and 5000 (MOLM-13) cells per well in the growth medium containing 10 %f etal calf serum (FCS). Cells were treated in quadruplicate with serial dilutions of test compounds for 96 h. Relative cell numbers were quantified by crystal violet staining (HeLa) [23] or CellTitre-Glo Luminescent Cell Viability Assay (Promega) (MOLM-13). IC 50 values (inhibitory concentration at 50 %o fm aximal effect) were determined by means of af our-parameter fit on measurement data which were normalized to vehicle (DMSO) treated cells (= 100 %) and measurement readings taken immediately before compound exposure (= 0%).
Equilibrium shake flask solubilityassay
The thermodynamic solubility of compounds in water was determined by an equilibrium shake flask method. [24] As aturated solution of the test compound was prepared and the solution was mixed for 24 ht oe nsure that equilibrium was reached. The solution was centrifuged to remove the insoluble fraction and the concentration of the compound in solution was determined using a standard calibration curve. To prepare the test sample, solid compound (2 mg) was weighed in a4 -mL glass vial. Phosphate buffer pH 6.5 (1 mL) was added and the suspension was stirred for 24 h at RT.T hen, the solution was centrifuged. To prepare the sample for the standard calibration, solid sample (2 mg) was dissolved in MeCN (30 mL). After sonication, the solution was diluted with water to 50 mL. Sample and standard were quantified by HPLC with UV detection. For each test sample, two injection volumes (5 and 50 mL) in triplicate were made. Three injection volumes (5 mL, 10 mLa nd 20 mL) were made for the standard. HPLC conditions: column:X terra MS C 18 2.5 mm, 4.6 30 mm;i njection volume: sample:3 5 mLa nd 3 50 mL, standard:5mL, 10 mLa nd 20 mL; flow: 1. ), were determined using Waters Empower 2FRsoftware.
Pharmacokinetic studies
For the metabolic stability assay in rat hepatocytes, liver cells were distributed in Williams' Medium Ec ontaining 5% FCS to glass vials at ad ensity of 1.0 10 6 vital cells mL À1 .T he test compound was added at afinal concentration of 1 mm.During incubation, the hepatocyte suspensions were continuously shaken at 580 rpm and aliquots were removed at 2, 8, 16, 30, 45 and 90 min, to which an equal volume of cold MeCN was immediately added. Samples were frozen at À20 8Co vernight, then centrifuged for 15 min at 3000 rpm. The supernatants were analyzed by liquid chromatogra-phy-tandem mass spectrometry (LC-MS/MS) using an Agilent 1200 HPLC system with an Ascentis Express column and water/MeCN (isocratic) as eluent. The half-life of at est compound was determined from the concentration-time plot and the intrinsic clearances were calculated. To gether with the additional parameters liver blood flow and amount of liver cells in vivo and in vitro, and application of the "well-stirred" liver model, [25] the hepatic in vivo blood clearance (CL b )a nd the maximal oral bioavailability (F max )w ere calculated.
The inhibitory potency of the test compounds toward cytochrome P450 dependent metabolic pathways was determined in human liver microsomes by applying individual CYP isoform-selective standard probes (CYP1A2, phenacetin;C YP2C8, amodiaquine;C YP2C9, diclofenac;C YP2D6, dextromethorphan;C YP3A4, midazolam). Reference inhibitors were included as positive controls. Incubation conditions (protein and substrate concentration, incubation time) were optimized with regard to linearity of metabolite formation. Assays were processed in 96-well plates at 37 8Cbyusing aGenesis Workstation (Tecan, Crailsheim, Germany). After protein precipitation, the metabolite formation was quantified by LC-MS/MS analysis followed by inhibition evaluation and IC 50 calculation.
To evaluate the CYP induction potential in vitro, cultured human hepatocytes from three separate livers were treated once daily for three consecutive days with vehicle control, one of eight concentrations of test compound and known human CYP inducers (e.g., omeprazole, phenobarbital, rifampin). After treatment, the cells were incubated in situ with the appropriate marker substrates for the analysis of CYP3A4 and CYP1A2 activity by LC-MS/MS.
Caco-2 cells (purchased from the German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) were seeded at a density of 4.5 10 4 cells per well on 24-well insert plates, 0.4 mm pore size, and grown for 15 days in DMEM supplemented with 10 %F CS, 1% GlutaMAX (100x, GIBCO), 100 UmL À1 penicillin, 100 mgmL À1 streptomycin (GIBCO) and 1% nonessential amino acids (100 ). Cells were maintained at 37 8Ci nahumidified 5% CO 2 atmosphere. The medium was changed every 2-3 d. Before running the permeability assay,t he culture medium was replaced with an FCS-free HEPES/carbonate transport buffer pH 7.2. For assessment of monolayer integrity,t he transepithelial electrical resistance was measured. Te st compounds were predissolved in DMSO and added either to the apical or basolateral compartment at a final concentration of 2 mm.B efore and after incubation for 2h at 37 8C, samples were taken from both compartments. LC-MS/MS analysis of compound content was undertaken after precipitation with MeOH. Permeability (P app )was calculated in the apical to basolateral (A!B) and basolateral to apical (B!A) directions. The efflux ratio basolateral (B) to apical (A) was calculated by dividing P app B!Ab yP app A!B.
For rat PK studies, test compounds were administered to male Wistar rats intravenously at low doses of 0.3 to 0.5 mg kg À1 and intragastrically at doses of 0.6 to 1mgkg À1 formulated as solutions using solubilizers such as PEG 400 in well-tolerated amounts. Animals were catheterized at the jugular vein and samples were taken via the catheter.P lasma samples were collected after 2min (only intravenously), 8min, 15 min, 30 min, 45 min, 1h,2h, 4h,6h, 8h and 24 hp ost-application, and precipitated with ice-cold MeCN (1:5). Supernatants were analyzed by LC-MS/MS. Pharmacokinetic parameters were based on the plasma concentration-time data and calculated (e.g.,u sing the linear-log trapezoidal rule for AUC estimation) with KinEx, an Excel-based program.
MOLM-13 and MV4-11human AML tumor models in mice and rats
All animal experiments were conducted in accordance with the German Animal Welfare Law and approved by local authorities. For the acute myeloid leukemia (AML) mouse model, 2 10 6 MOLM-13 human AML cells were suspended in 100 %M atrigel TM Basement Membrane Matrix (BD Biosciences) and inoculated subcutaneously to the left flank of female NMRI nu/nu mice (18-21 g, 5-6 weeks, Taconic M&B). For the AML model in rats, 2 10 6 MV4-11h uman AML cells were suspended in 100 %M atrigel TM and inoculated subcutaneously to the left flank of female athymic nude rats (160-200 g, 5-6 weeks, Harlan). Animals were stratified into treatment and control groups (n = 8-13/group for mice, n = 12/group for rats) based on primary tumor size. Treatments were started 3-13 days after tumor cell inoculation when the average tumor sizes were 23-38 mm 2 and 43 mm 2 for mice and rats, respectively.
BAY1 143572 was administered either using ao nce daily (QD) or an intermittent 3days on/2 days off treatment schedule. BAY-958 hydrochloride and compound 4 were administered QD. PEG 400/ water 80:10 was used as the vehicle control. Unless otherwise indicated, all treatments were administered orally (p.o.) and were continued until the end of the experiment. Body weight and tumor areas (longest diameter multiplied by its perpendicular) measured by caliper were determined at least twice weekly.T reatment-tocontrol (T/C) ratios were calculated by dividing the mean tumor area of the treatment group by the mean tumor area of the vehicle group at the time point when the vehicle group was sacrificed.
All statistical analyses were performed using statistical software R (version 3.3.2) by comparing the treatment groups to the vehicle group at the time point when the vehicle group was sacrificed. Statistical analysis of the log-transformed tumor area data was performed using one-way ANOVAf ollowed by Dunnett'sc ontrasts or Kruskal-Wallis test followed by Dunn's test with Holm-Bonferroni correction. In the MV4-11m odel with only two groups, the analysis was performed using Student's t test. In all cases, p < 0.05 was considered as being statistically significant.
Docking
Docking calculations were performed using Glide [26] in standard precision mode and default settings. The X-ray complex of CDK9/ CycT1 with ab enzimidazole inhibitor (PDB ID:3 MY1) was used. [27] Prior to the docking procedure, all water molecules and ligands in the protein-ligand complex were removed. Ligands were pre-processed using LigPrep. [28] Docking poses were selected based on Glide scoring.
Synthetic procedures
General methods and materials:C ommercially available reagents and anhydrous solvents were used as supplied, without further purification. All air-and moisture-sensitive reactions were carried out in oven-dried (at 120 8C) glassware under an inert atmosphere of argon. AB iotage Initiator Classic microwave reactor was used for reactions conducted in am icrowave oven. Reactions were monitored by TLC and UPLC analysis with aW aters Acquity UPLC MS Single Quad system;c olumn:A cquity UPLC BEH C 18 1.6-2.0 min 99 %B ;f low: 0.8 mL min À1 ;t emperature:6 0 8C; DAD scan:2 10-400 nm. Analytical TLC was carried out on aluminumbacked plates coated with Merck Kieselgel 60 F 254 ,w ith visualization under UV light at 254 nm. Flash chromatography was carried out using aB iotage Isolera TM One system with 200-400 nm variable detector.P reparative HPLC was carried out with aW aters AutoPurification MS Single Quad system;c olumn:W aters XBridge C 18 5 mm, 100 30 mm;b asic conditions:e luent A: H 2 O + 0.2 vol %a q. NH 3 (32 %), eluent B: MeCN;g radient:0 -0.5 min 5% B, flow: 25 mL min À1 ;0 .51-5.50 min 10-100 %B ,f low: 70 mL min À1 ;5 .51-6.5 min 100 %B ,f low: 70 mL min À1 ;a cidic conditions:e luent A: H 2 O + 0.1 vol %f ormic acid (99 %), eluent B: MeCN;g radient:0 -0.5 min 5% B, flow: 25 mL min À1 ;0 .51-5.50 min 10-100 %B ,f low: 70 mL min À1 ;5 .51-6.5 min 100 %B ,f low: 70 mL min À1 ;t emperature: 25 8C; DAD scan:2 10-400 nm. NMR spectra were recorded at ambient temperature (22 AE 1 8C), unless otherwise noted, on Bruker AvanceI II HD spectrometers. 1 HNMR spectra were obtained at 300, 400, 500 or 600 MHz, and referenced to the residual solvent signal (7.26 ppm for CDCl 3 ,2 .50 ppm for [D 6 ]DMSO).
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CNMR spectra were obtained at 125 MHz and also referenced to the residual solvent signal (39.52 ppm for [D 6 ]DMSO). 1 HNMR data are reported as follows:c hemical shift (d)i np pm, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet) and integration. High-resolution mass spectra were recorded on aX evo G2-XS To f( Waters) instrument. Low-resolution mass spectra (electrospray ionization) were obtained via HPLC-MS (ESI) using a Waters Acquity UPLC system equipped with an SQ 3100 Mass Detector;c olumn:A cquity UPLC BEH C 18 1.7 mm, 50 2.1 mm;e luent A: H 2 O + 0.05 %f ormic acid (99 %), eluent B: MeCN + 0.05 %f ormic acid (99 %);g radient:0 -0.5 min 5% B, 0.5-2.5 min 5-100 %B ,2 .5-4.5 min 100 %B;t otal run time:5min;f low: 0.5 mL min À1 .M elting points were determined with aB üchi B-540 melting point apparatus. Optical rotations were recorded on aJ ASCO P-2000 polarimeter.T he purity of all target compounds was > 97 %, as determined by 1 HNMR spectroscopy. Chloro-1,3 ,5-triazin-2-yl)amino]benzenemethanesulfonamide:T oasolution of 2,4-dichloro-1,3,5-triazine (1;9 00 mg, 6.0 mmol) in anhyd. THF/iPrOH (1:1, 8mL) at À20 8Cu nder N 2 atmosphere was added ac ooled solution (À20 8C) of (3-aminophenyl)methanesulfonamide (1117mg, 6.0 mmol) and DIPEA (2.07 mL, 12 mmol) in anhyd. THF/iPrOH (1:1, 8mL). The reaction mixture was stirred for 2hat À10 8C. The mixture was concentrated under reduced pressure and the crude product was dried in vacuo for 15 h. The white solid was used in the next step without further purification: 1-[(Methylsulfanyl)methyl]-3-nitrobenzene:S odium methanethiolate (13.5 g, 192 mmol) was added in two portions to astirred solution of 1-(chloromethyl)-3-nitrobenzene (30.0 g, 175 mmol) in EtOH (360 mL) at À15 8C. The cold bath was removed and the mixture was stirred at RT for 3h.T hen, it was diluted with brine and extracted with EtOAc (2 ). The combined organic phases were washed with water,d ried (Na 2 SO 4 ), filtered and concentrated to give the desired product (32.2 g) that was used without further purification: 
3-[(4-

1-[(Methylsulfonyl)methyl]-3-nitrobenzene:
3 -Chloroperoxybenzoic acid (77 %; 26.9 g, 120 mmol) was added to as tirred solution of 1-[(methylsulfanyl)methyl]-3-nitrobenzene (10.0 g) in CH 2 Cl 2 (1305 mL) at 0 8C. The mixture was stirred at 0 8Cf or 30 min and then at RT for 2.5 h. Then, it was diluted with water (300 mL), and NaHCO 3 (11.0 g) was added. The mixture was extracted with CH 2 Cl 2 (2 ). The combined organic phases were filtered using aW hatman filter and concentrated. The residue was purified by flash chromatography (CH 2 Cl 2 /EtOH, 95:5) and finally recrystallized from EtOAc to give the desired product (6.2 g, 28. ) at RT,a nd the mixture was stirred for 16 h. The pH was increased to 10 by the addition of 1 n NaOH, then the reaction mixture was extracted with EtOAc (2 ). The combined organic phases were washed with brine, filtered using aW hatman filter and concentrated to give the desired product (4.5 g) that was used without further purification: Chloro-N-[3-(methylsulfonyl)phenyl]-1,3 ,5-triazin-2-amine: DIPEA (0.31 mL, 1.75 mmol) was added to as tirred solution of 2,4-dichloro-1,3,5-triazine (1;1 38 mg, 0.88 mmol) in THF/iPrOH (1:1, 1.8 mL) at À40 8C. Then, as uspension of 3-(methylsulfonyl)aniline (150 mg, 0.88 mmol) in THF/iPrOH (1:1, 0.9 mL) was added at this temperature. Under stirring, the temperature of the reaction mixture was slowly raised over 90 min to 0 8C. The mixture was concentrated in vacuo to give the crude product (450 mg) that was used without further purification. 4 (274 mg, 0.24 mmol) in 1,2-dimethoxyethane (7.3 mL) and aq. 2 m K 2 CO 3 (1.6 mL) was degassed using argon. The mixture was stirred under argon for 90 min at 100 8C. After cooling, the mixture was diluted with EtOAc and washed with brine. The organic phase was filtered using aW hatman filter and concentrated. 1, 1mL ) was added at this temperature. Under stirring, the temperature of the reaction mixture was slowly raised over 2h to 0 8C. The mixture was concentrated in vacuo to give the crude product (458 mg) that was used without further purification. 4 (83 mg, 0.07 mmol) in 1,2-dimethoxyethane (1.5 mL) and aq. 2 m K 2 CO 3 (0.5 mL) was degassed using argon. The mixture was stirred under argon for 90 min at 100 8C. After cooling, the mixture was diluted with EtOAc and washed with brine. The organic phase was filtered using aW hatman filter and concentrated. The residue was purified by preparative HPLC (acidic conditions) to give 6 as a light beige solid (53 mg, 0.13 mmol): 1 After cooling, the mixture was diluted with EtOAc and THF,a nd washed with brine. The organic phase was filtered using aW hatman filter and concentrated. The residue was purified by preparative HPLC (acidic conditions) to give 9 as al ight beige solid (30 7 mL) at RT,a nd the mixture was stirred for 16 h. The pH was increased to 10 by the addition of 2 n NaOH, then the reaction mixture was extracted with EtOAc (2 ). The combined organic phases were washed with brine, dried (Na 2 SO 4 ), filtered and concentrated to give the crude product (88 mg) that was used without further purification. 4 (129 mg, 0.11mmol) in 1,2-dimethoxyethane (2.3 mL) and aq. 2 m K 2 CO 3 (0.7 mL) was degassed using argon. The mixture was stirred under argon for 90 min at 100 8C. After cooling, the mixture was diluted with EtOAc and THF,a nd washed with brine. The organic phase was filtered using aW hatman filter and concentrated. The residue was purified by preparative HPLC (acidic conditions) to give 10 as al ight beige solid (34 mg, 0.08 mmol): 
4-
4-(4-
3-[2-(Methylsulfonyl)propan-2-yl]aniline:T iCl 3 solution (ca. 15 % in~10 %HCl, 3.8 mL) was added to astirred solution of 1-[2-(methylsulfonyl)propan-2-yl]-3-nitrobenzene (135 mg, 0.56 mmol) in THF (5.8 mL) at RT,a nd the mixture was stirred for 16 h. The pH was increased to 10 by the addition of 2 n NaOH, then the reaction mixture was extracted with EtOAc (2 ). The combined organic phases were washed with brine, dried (Na 2 SO 4 ), filtered and concentrated to give the crude product (148 mg) that was used without further purification.
4-Chloro-N-{3-[2-(methylsulfonyl)propan-2-yl]phenyl}-1,3,5-triazin-2-amine:D IPEA (0.24 mL, 1.37 mmol) was added to as tirred solution of 2,4-dichloro-1,3,5-triazine (1;1 03 mg, 0.68 mmol) in THF/iPrOH (1:1, 1.3 mL) at À40 8C. Then, as olution of crude 3-[2-(methylsulfonyl)propan-2-yl]aniline (146 mg) in THF/iPrOH (1:1, 0.6 mL) was added at this temperature. Under stirring, the temperature of the reaction mixture was slowly raised over 2h to 0 8C. The mixture was concentrated in vacuo to give the crude product (354 mg) that was used without further purification.
4-fluoro-2-methoxyphenylboronic acid (65 mg, 0.38 mmol) and Pd(PPh 3 ) 4 (66 mg, 0.06 mmol) in 1,2-dimethoxyethane (1.2 mL) and aq. 2 m K 2 CO 3 (0.4 mL) was degassed using argon. The mixture was stirred under argon for 90 min at 100 8C. After cooling, the mixture was diluted with EtOAc and THF,a nd washed with brine. The organic phase was filtered using aW hatman filter and concentrated. The residue was purified by preparative HPLC (acidic conditions) to give 11 as al ight beige solid 1 mL) was degassed using argon. The mixture was stirred under argon for 90 min at 100 8C. After cooling, the mixture was diluted with EtOAc and THF, and washed with brine. The organic phase was filtered using a Whatman filter and concentrated. The residue was purified by preparative HPLC (acidic conditions) to give 12 as al ight beige solid (5 mg 3 (0.1 mL) was degassed using argon. The mixture was stirred under argon for 90 min at 100 8C. After cooling, the mixture was diluted with EtOAc and THF,a nd washed with brine. The organic phase was filtered using aW hatman filter and concentrated. The residue was purified by preparative HPLC (acidic conditions) to give 13 as aw hite solid (6 1-(3-{[4-(2,4-Difluorophenyl)-1,3,5-triazin-2-yl] trifluoro-N-[methyl(3-nitrobenzyl)oxido-l 6 -sulfanylidene]acetamide (25.6 g,~82.4 mmol) in MeOH (1768 mL) at RT.T he mixture was stirred for 1h at RT,t hen diluted with EtOAc and brine, and extracted with EtOAc (2 ). The combined organic phases were dried (Na 2 SO 4 (rac)-Ethyl [methyl(3-nitrobenzyl)oxido-l 6 -sulfanylidene]carbamate (28):E thyl chlorocarbonate (8.1 mL, 84.6 mmol) was added dropwise to astirred solution of (rac)-27 (13.9 g, 65.1 mmol) in pyridine (615 mL) at 0 8C. The mixture was slowly warmed to RT.A fter 24 h, the mixture was concentrated and the residue was dissolved in EtOAc and washed with brine. The organic phase was filtered using aW hatman filter and concentrated to give (rac)-28 (19.7 g) that was used without further purification: -sulfanylidene]carbamate (29):T iCl 3 solution (ca. 15 %i n~10 %H Cl, 118mL) was added to as tirred solution of (rac)-28 (5.0 g,~17.5 mmol) in THF (220 mL) at RT,a nd the mixture was stirred for 18 h. The solution was brought to pH 8b yt he addition of 2 n NaOH to the reaction mixture, which was cooled with an ice bath. The mixture was saturated with solid NaCl and extracted with EtOAc (3 ). The combined organic phases were washed with brine, dried (Na 2 SO 4 ), filtered and concentrated to give (rac)-29 (4.2 g, 16.5 mmol, 94 %) that was used without further purification: -sulfanylidene]acetamide (33):A cetyl chloride (22 mg, 0.28 mmol) was added dropwise to as olution of BAY1 143572 (100 mg, 0.26 mmol) in TEA (31 mg, 0.31 mmol) and CH 2 Cl 2 (3.0 mL) at 0 8C. The ice bath was removed and the mixture was stirred at RT for 3h.T hen, the mixture was diluted with water and extracted with CH 2 Cl 2 (3 ). The combined organic phases were filtered using aW hatman filter and concentrated. The residue was purified by preparative HPLC (acidic conditions) to give 33 as aw hite solid (63 mg, 0. 15 
X-ray structure determinationof33
Single crystals of 33 were obtained by slow evaporation of an ethyl acetate solution of 33 at RT.As ingle crystal was mounted on aC ryoLoop using inert oil. Data collection was carried out using a Bruker diffractometer equipped with an APEX II CCD area detector, an ImSm icrosource with Cu Ka radiation, mirrors as monochromator and aK ryoflex low temperature device (T = 110K). The program APEX II v.2011.8-0 was used for data collection and reduction. [29] Absorption correction and scaling was performed using SADABS. [30] The crystal structure solution was achieved using direct methods as implemented in SHELXTL version 6.14 [31] and visualized using the XP program. [31] Missing atoms were subsequently located from difference Fourier synthesis and added to the atom list. Leastsquares refinement on F 2 using all measured intensities was carried out using the program SHELXTL version 6.14. [31] All non-hydrogen atoms were refined including anisotropic displacement parameters. Final data collection and structure refinement parameters: l = 
